Pharmacyclics billionaire Bob Duggan takes the helm of another biotech — and he faces an even bigger uphill climb this time
Five years after turning his stake in Pharmacyclics into a personal fortune worth more than a billion dollars, Bob Duggan is back at the helm of a biotech. He’s once again fighting the odds in making a biotech a success — but this time instead of oncology, where he made biotech history with Imbruvica, he’s taken the reins on a late-stage program for an antibiotic.
And nothing is quite as chilly right now as antibiotics.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.